-

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against CSX Corporation (CSX)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against CSX Corporation (“CSX” or the “Company”) (NASDAQ: CSX). The investigation concerns whether CSX and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On October 17, 2024, Bloomberg published an article stating that CSX “received a subpoena from the US Securities and Exchange Commission” relating to “previously disclosed accounting errors and certain non-financial performance metrics.” According to the Bloomberg article, “The subpoena asked the railroad company to produce documents about accounting mistakes CSX disclosed in its previous quarterly report, according to a regulatory filing on Thursday. The company received the subpoena this month and is cooperating with the probe, CSX said in the filing.” On this news, the price of CSX shares declined by $2.38 per share from $35.47 per share on October 17, 2024, to close at $33.09 on October 18, 2024.

If you purchased or otherwise acquired CSX securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:CSX

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

GE HEALTHCARE TECHNOLOGIES INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against GE HealthCare Technologies Inc. (“GE HealthCare” or the “Company”) (NASDAQ:GEHC). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 29, 2026, GE HealthCare reported its financial results for the first quar...

ERASCA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ:ERAS). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 28, 2026, Erasca disclosed receipt of a letter from Revolution Medicines alleging that Erasca’s ERA...

QIAGEN N.V. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 5, 2026, Qiagen released fourth quarter 2025 earnings and stated that QuantiFERON would accelerate...
Back to Newsroom